• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Influenza Vaccine Effectiveness Against Mild and Severe Outcomes: A Comparison Study in Portugal

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses

. 2026 Sep;20(9):e70299.
doi: 10.1111/irv.70299.

Influenza Vaccine Effectiveness Against Mild and Severe Outcomes: A Comparison Study in Portugal​


Francisco Mourao 1 , Verónica Gómez 2 , Patrícia Soares 2 , Ana Paula Rodrigues 2 , Carlos Matias Dias 2 , Ausenda Machado 2

Affiliations


Abstract​


Background: Influenza vaccination is an effective public health intervention to lessen influenza effect on healthcare and has been recommended to prevent severe outcomes. Previous studies present higher influenza vaccine effectiveness (IVE) estimates against primary care medically attended (outpatients) compared to hospitalised cases (inpatients). Inconsistencies in study designs may hinder comparisons of IVE in preventing mild (outpatient consultations) versus severe influenza (inpatient admissions). We aimed to compare IVE against mild and severe influenza within primary care and hospital networks in Portugal from 2015/16 to 2023/24.


Methods: Using the test-negative design, we analysed 3393 RT-PCR-tested patients with influenza-like illness in outpatients or severe acute respiratory infection in inpatients. IVE was estimated using a generalised linear mixed model with fixed effects for sex, age category, comorbidities, month of symptom onset and random effects for season. For difference estimation, 95% confidence intervals (CI) were obtained through bootstrapping.


Results: IVE was 40.4% (22.7; 54.0) for outpatients and 38.7% (17.6; 54.5) for inpatients. The 1.7% difference was not statistically significant (-22.0; 26.8). Subgroup analyses for individuals aged ≥ 65 years, patients with comorbidities and by influenza A subtype showed similar non-significant differences, ranging from -1% to 17%.


Conclusion: We found no statistically significant difference in IVE against mild or severe influenza infection. However, comparison across care settings should be interpreted cautiously, as patients differ in sociodemographic characteristics and comorbidity burden. Although limited sample size may reduce statistical power, the small magnitude of observed differences suggests that patients benefit from current vaccination strategies across care settings.

Keywords: hospital; influenza; influenza like illness; influenza vaccine; primary care; severe acute respiratory infection; vaccine effectiveness.
 
Back
Top Bottom